Manufacturers report positive results for asciminib in chronic myeloid leukaemia in phase III trial

In the ASCEMBL study, asciminib, a selective allosteric inhibitor of BCR-ABL met its primary endpoint of superiority vs bosutinib in inducing a major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.